Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 104

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 104
---
 loyalty to us or our stockholders; |

| ● | for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; |

| ● | for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or |

| ● | for any transaction from which the director derived an improper personal benefit. |

58

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

The following description of our common stock, Pre-Funded Warrants and accompanying Series Warrants underlying the Units summarizes the material terms and provisions of the securities that we may issue in connection with this offering. It may not contain all the information that is important to you. For the complete terms of our common stock, please refer to our Articles of Incorporation and By-Laws which are filed as exhibits to the registration statement which includes this prospectus. See “Where You Can Find More Information”. The Delaware General Corporation Law (“DGCL”) may also affect the terms of these securities. The summary below is qualified in its entirety by reference to our Articles of Incorporation and By-Laws, each as in effect at the time of any offering of securities under this prospectus.

As of February 13, 2025, our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share, of which 11,319,039 shares were issued and outstanding, and 50,000,000 shares of preferred stock, par value $0.0001 per share, of which 567.85 shares of Series A Preferred Stock were issued and outstanding and 0 shares of Series B Preferred Stock were issued and outstanding. In addition, as of February 13, 2025, there were 420,133 shares of common stock issuable upon exercise of options outstanding, 8,106,821 shares of common stock issuable upon exercise of warrants outstanding and 47,658 shares of common stock reserved for future grant or issuance, which, in each case, does not give effect to the issuance of the Stock Awards in the amount of 2,200,000 shares of restricted shares of common stock to be issued to certain directors and officers of the Company, subject to the closing of this offering. The authorized and unissued shares of common stock and preferred stock are available for issuance without further action by our stockholders.

Common Stock

We have never declared or paid any cash dividends on our common stock. So long as